OPHTALMOLOGY

Cite as: Archiv EuroMedica. 2025. 15; 1. DOI 10.35630/2025/15/1.106

Received 20 December 2024;
Accepted 14 February 2025;
Published 20 February 2025

MODERN TECHNOLOGIES IN THE DIAGNOSIS AND TREATMENT OF RETINAL DISEASES - A LITERATURE REVIEW

Kamil Gibczynski[1] ✉, Martyna Orzechowska[2], Karolina Jablonska[2], Karol Lesniewski[2], Piotr Paluch[2], Aleksandra Roztoczyńska[2], Michal Orczyk[2], Anita Król[1], Aleksandra Jeńć-Magoń[2], Jakub Pudźwa[2]

[1]Fryderyk Chopin University Clinical Hospital in Rzeszow, Poland
[2]College of Medical Sciences, University of Rzeszow, Poland

download article (pdf)

✉ kamilgibczynski12@gmail.com

ABSTRACT

Background: Retinal diseases like age-related macular degeneration (AMD), diabetic retinopathy, or retinal detachment are a challenging area for modern medicine, making a significant impact on patients' quality of life and increasing prevalence in the aging population. Advanced diagnostic and therapeutic technologies in these pathological conditions allow for accurate surveillance of pathological alterations and enhancement of therapeutic efficacy rooted in precise molecular biology knowledge.

Objective: This paper focuses on presenting the latest advancements in the field of ocular disease diagnostics, with a particular emphasis on retinal diseases. Modern studies, including optical coherence tomography (OCT), OCT angiography (OCTA), and other strategies based on artificial intelligence (AI), are profoundly transforming diagnostic methods in the prevention, early detection, and monitoring of retinal changes. The review also highlights novel therapeutic strategies, such as the latest biologic drugs, gene therapy, nanomedicine technologies, and retinal implants.

Conclusions: Conducted literature analysis supports that new technologies, including optical coherence tomography (OCT) and OCT angiography (OCTA), biological therapies, gene therapies, and artificial intelligence, are significant breakthroughs in retinal disease diagnosis and treatment. However, major obstacles such as accessibility to these technologies, therapy pricing, and lack of long-term safety and efficacy studies require further research and application. Although efforts have been made to ensure these devices are generally affordable, more needs to be done to make them both cost-effective and efficient to promote accessibility to the advanced treatment options and improve the quality of life for patients with retinal disturbances.

Keywords: AMD, OCT, diabetic retinopathy, retinal detachment, OCTA, anti-VEGF therapy, artificial intelligence in ophthalmology

INTRODUCTION

Age-related macular degeneration (AMD) is one of the most common causes of irreversible visual impairment in the elderly population, occurring in roughly 8% of individuals greater than 50 years old and ~40% of those over 80 years old. It is estimated that in Poland, between 1 and 1.5 million people suffer from AMD, with figures projected to rise as the population ages. Worldwide, AMD cases are expected to rise to almost 300 million by 2040 from about 200 million today. A timely diagnosis and proper treatment can greatly slow the progression of the disease and enhance patients' quality of life.

In recent years, the dynamic development of medical technologies has fundamentally transformed approaches to both the diagnosis and treatment of numerous diseases, including retinal disorders. Significant advancements in fields such as imaging—particularly OCT and OCTA—molecular biology, artificial intelligence, and nanotechnology have paved the way for breakthroughs that were considered nearly unattainable just a few years ago. Retinal diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), are now among the leading causes of vision loss both in Poland and globally, making them a priority area for research and development.

Although there are many literature reviews on these technologies, most focus on specific aspects, such as a particular diagnostic test or treatment method. The need for a comprehensive overview of the current state of knowledge motivated the creation of this review. It integrates various innovations in diagnostics and treatment into a coherent whole, allowing for a better understanding of their significance and potential while identifying the challenges and obstacles associated with implementing these methods in clinical practice.

The aim of this paper is not only to present the latest technological advancements in the diagnosis and treatment of retinal diseases but also to highlight gaps in the existing review literature in this field. Particular attention is given to imaging methods, biological and genetic therapies, the use of nanotechnology, and artificial intelligence in the diagnosis and treatment of conditions such as AMD and DR. This comprehensive approach sheds light on how these advancements contribute to improved prognosis, quality of life, and early detection of retinal diseases.

Unfortunately, limitations of these innovations are also evident and are critically discussed in this article. Among these, the most significant appear to be the lack of access to technology and the need for long-term studies on their safety and efficacy. The paper provides a comprehensive review of the available medical and scientific literature, emphasizing future research directions and highlighting the potential for further revolutionizing the management and treatment of patients suffering from retinal diseases.

This literature review is important because, admittedly there exists literature on modern approaches to diagnostic and therapeutic modalities for treating retinal diseases, but no comprehensive synthesis has been reached yet spanning the current advancements with a broad spectrum of integrated solutions across multiple disciplines, specifically imaging, artificial intelligence, gene therapy, and nanomedicine. Our review is focused on the challenges of bringing these innovations into clinical care and identifies emerging technologies with the potential to revolutionize patient engagement. We also discuss the limitations of existing therapies, including accessibility challenges and safety of chronic use, offering a unique outlook on the future of retinal disease treatment.

OBJECTIVES

We attempted to introduce and discuss contemporary technologies for the diagnosis and treatment of retinal diseases. Our review investigates modern technologies for the diagnosis and treatment of retinal diseases.

METHODS

The literature review integrated scientific articles, systematic reviews, and reports from reputable medical and ophthalmological journals. Priority was given to publications from the past 10 years (2014–2024) to ensure that the data remained relevant; however, seminal works that formed the basis of the technologies discussed were exceptions. Searches of literature were performed using scientific databases, namely PubMed, Web of Science, and Google Scholar.

RESULTS: DIAGNOSIS TECHNOLOGIES

This section highlights the most notable advancements in diagnostic technologies for retinal diseases, encompassing cutting-edge imaging methods, the integration of artificial intelligence, and innovative therapeutic approaches. It also emphasizes how these developments are reshaping clinical practices and improving patient outcomes.

High technology progress in diagnostics and treatment of retinal diseases was confirmed in the literature analysis. As a major advancement in retinal diagnostics, optical coherence tomography (OCT) allows for high-resolution imaging of retinal layers, with the detection of pathologies like macular edema and neovascular membranes. In addiction, Optical Coherence Tomography-Angiography (OCTA) has transformed the non-invasive imaging of retinal microcirculation, enabling early detection of the alterations observed with vascular changes in diabetic retinopathy and age-related macular degeneration (AMD).

AI and machine learning have become vital tools in the ophthalmology space. Another approach is AI algorithms, which are effective to be used for the analysis of computer-based images, such as the OCT and OCTA images, helping in the diagnostic accuracy of retinal diseases and predicting the result of the treatment. Biological therapies, such as anti-VEGF agents including ranibizumab and aflibercept, have substantially improved clinical outcomes in patients with AMD and macular edema, minimizing the risk of vision loss. But the drawbacks, including the requirement for repeated injections and high expense, highlight the need for more research into long-lasting solutions. Despite those advancements, there are challenges. Therapies can be expensive, advanced devices are not easily accessible, and there is skepticism about how AI can be implemented in clinical practice. Confronting these problems and delivering less expensive, automated, and robust therapeutic tools will be key initiatives in advancing the field of retinal disease.

RESULTS

Age-related macular degeneration (AMD) is a progressive disease that primarily involves the macula lutea, the central portion of the retina. Its development is the result of a complex interaction of aging, genetic predispositions, and environmental risk factors. Worldwide, AMD is responsible for around 6% to 9% of blindness [1]. AMD presently affects approximately 196 million individuals across the world. Ranked among the top three etiologies for the commonest cause of significant visual impairment found among an elderly population, it is expected to impact an estimated 288 million people globally by 2040 [1,7].

Diabetic retinopathy (DR) is a microangiopathy that results from long-term exposure to diabetes mellitus (DM), and it is the most common retinal vascular disease. After 15 years of diabetes, 1 in 4 becomes affected by DR; in 2020, DR was the fifth leading cause of preventable blindness in adults globally and the fifth leading cause of moderate to severe vision impairment (MSVI) in individuals aged 50 or older [2].

Retinal detachments occur when vitreous fluid leaks through a tear or hole in the retina, separating the retina from the underlying choroid. If not treated promptly, this can lead to a loss of vision. The risk of suffering from retinal detachment in a lifetime is roughly 0.1%; however, there are factors that can raise the chances of its occurrence. Some of these factors include being older in age, having high myopia (greater than -6.0 diopters), a history of eye trauma or prior eye surgeries, and a positive family history of retinal detachment. Individuals with these risk factors are at higher risk of developing retinal detachment that, if untreated, can adversely affect vision [3, 4].

DIAGNOSTIC TECHNOLOGIES

OCT uses sophisticated optical principles (namely, coherence and interferometry) to produce superior cross-sectional images of internal body structures. This precise imaging technique is based on the wave theory of light energy, reflecting that light behaves as a wave. By exploiting the interactions of light waves with tissue, OCT can achieve outstanding resolution to be able to picture very fine details of the biological tissue, with an emphasis on the eye.

Optical Coherence Tomography Angiography (OCTA) is an exciting extension of this technology, which is a major advance in imaging modalities. Optical coherence tomography angiography (OCTA) is a rapid, noninvasive imaging modality that offers a real-time cross-sectional perspective of the angioarchitecture of the dynamic microvasculature of the retina and choroid. OCTA constructs angiograms using motion contrast produced by moving blood cells, as opposed to the need for contrast dyes to be injected with traditional angiography [5]. OCTA obtains a high pixel density to precisely map tissue and underlying blood flow, providing a detailed assessment of vascular structures and ischemic regions in a range of conditions. Leveraging this capacity enables reliable quantification as well as the mapping of vascular pathologies, making OCTA a powerful tool for the clinician in eye care. OCT has become the gold standard for diagnosing a variety of common retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), central serous chorioretinopathy (CSC), and macular telangiectasia (MacTel). OCTA has proven to be essential in both the detection and management of these disease states, as it provides detailed vascular mapping non-invasively [8].

The widespread advancement and incorporation of deep learning (DL), machine learning (ML), and artificial intelligence (AI) technology within the past few years have led to important changes to help modern society. These advanced technologies have brought to us unimaginable degrees of automation, precision, and efficiency, changing the way we engage with the world around us. DL, ML, and AI have transformed everything, from improving healthcare diagnosis and optimizing transport networks to new communication channels, to making business more efficient and in all other areas of expertise. Especially applications based on deep learning (DL) attract considerable global attention focused on Artificial Intelligence (AI) recently because of their successful use in various domains including image recognition, speech recognition, analysis of spoken language, and even healthcare [9]. Among the many specialties within medicine, ophthalmology has been at the forefront of harnessing AI technologies. The integrated platform for ophthalmic diagnostics may already be in an ecosystem where AI systems are enhancing the work of ophthalmologists to better aggregate data—gathering data points that are dispersed in different databases and presenting them in an understandable format for the ophthalmologist in order to aid in clinical decision-making.

ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF RETINAL DISEASES

The increasing importance of AI in ophthalmology can also be explained, at least in part, by the specific nature of ocular structures, which are particularly transparent, and the existence of recent imaging techniques allowing the development of large and high-quality databases of digital images. These factors have allowed for the extraction of granular data that can be analyzed as part of AI-driven insights. Outside of its specific applications in eye care, AI in ophthalmology has tremendous potential for larger medical diagnostics. AI systems can analyze ocular images and measurements that can potentially detect and predict systemic conditions, including heart failure, ischemic stroke, and Parkinson's disease. Both these capabilities – that of monitoring an ophthalmic condition and monitoring for systemic diseases – suggest that AI can indeed revolutionize the specialty [9, 10].

However, the significant technological developments in diagnostic imaging modalities, along with the rapid proliferation of screening examinations, have raised challenges for a timely and accurate interpretation of imaging data. Conventional approaches based exclusively on human intelligence are falling behind in terms of data inputs, which is necessitating the exploration of decision-making support systems. The innovation of artificial intelligence (AI) exhibits a great promise in the automation of image classification and diagnosis of common retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR). And the AI technology is especially pivotal in analyzing data derived from optical coherence tomography (OCT) scans. Such machine learning models trained on massive datasets can suggest patient referral decisions more accurately than the specialists themselves, or at least as accurately. One AI-based diagnostic system trained on only 14,884 scans was shown to achieve expert-level performance in detecting sight-threatening retinal diseases [17].

One of the important applications of artificial intelligence (AI) in ophthalmology is the segmentation of retinal images, which allows accurate delineation of retinal structures and quantitative measurement of pathological changes. Such sophisticated techniques help to detect diseases at earlier stages, as well as to monitor the effectiveness of treatment.

While there are many benefits to AI in clinical practice, there are also some challenges to its implementation. These include technical differences in imaging techniques and the heterogenous manifestation of pathologies amongst patients. Thus, the advancement and fine-tuning of AI methods suited to the intricacies of ocular data are still very much a target for research aimed at harnessing artificial intelligence for the visualization and management of retinal disorder. [17,18].



Fig. 1 | Results of the segmentation network. Three selected two-dimensional slices from the n = 224 OCT scans in the segmentation test set (left) with manual segmentation (middle) and automated segmentation (right; detailed color legend in Supplementary Table 2). a, A patient with diabetic macular edema. b, A patient with choroidal neovascularization resulting from age-related macular degeneration (AMD), demonstrating extensive fibrovascular pigment epithelium detachment and associated subretinal fluid. c, A patient with neovascular AMD with extensive subretinal hyperreflective material. [17].

APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN RETINAL DISEASES

DIABETIC RETINOPATHY

Diabetic retinopathy (DR), one of the most prevalent complications of Diabetes Mellitus and a leading preventable cause of blindness, threatens 28.54 million individuals with visual impairment. The American Academy of Ophthalmology suggests annual screenings for DR [19, 27]. Artificially intelligent-based screening systems can help reduce costs and increase access to eye care, using algorithms to identify the presence of DR signs such as microaneurysms, hemorrhages, and vessel changes, evident in fundus images. The IDx-DR system, the first artificial intelligence (AI) for DR detection awarded FDA approval, detects DR biomarkers in color fundus photos, to determine if an ophthalmologist visit or screening is required. Using the Messidor-2 dataset, the system showed a sensitivity of 96.8% and specificity of 87%, while in clinical trials the sensitivity was 87.2% and specificity 90.9%.

EyeArt and Retmarker are the approved AI systems for DR screening in Europe. EyeArt had sensitivity 91.7%, specificity 91.5%. In terms of referring to specialist DR, the sensitivity of their test was 99.3% and for sight-threatening DR was 99.1% when images taken on a smartphone were tested. Retmarker can follow disease development by comparing currently taken images to those taken before with a sensitivity of 85% for referable DR and 97.9% for proliferative DR. The sensitivity of the EyeArt test was higher than Retmarker, but it leads to a higher false-positive rate [19].

Table 1. Summary of selected studies using artificial intelligence in the diagnosis, stages, and prognosis of diabetic retinopathy [20-26].

Study	Disease	AI Tool	Study Cohort/Database	Imaging Analyzed	Performance Metrics
Pires et al.	DR Diagnosis	CNN	Messidor-2 (1748 images), Kaggle (88702 images), DR2 (520 images)	CFP	Accuracy = 98,2 % (Messidor-2), 98% (DR2)
Jiang et al.	DR Diagnosis	CNN	30244 images	CFP	AUC = 0.946 Sensitivity = 85,57% Specifity = 90,85% Accuracy = 88,21 %
Esfahani et al.	DR Diagnosis	ResNet-34 (CNN)	Kraggle (35000 images)	CFP	Sensitivity = 85% Specifity = 86%
Abramoff et al.	DR Staging	CNN	Messidor-2 (1748 images)	CFP	AUC = 0,98 Sensitivity = 96,8% Specifity = 87%
Pratt et al.	DR Staging	CNN	Kraggle (35000 images)	CFP	Sensitivity = 30% Specifity = 95% Accuracy = 75%
Zhang et al.	DR Grading	ResNet-34, Inception v3 (CNN)	1089 images	CFP	AUC = 0,958 Kappa = 0,860
Katz et al.	DR Grading	W-net (CNN)	6981 images	CFP	Accuracy = 98,9%

DR - diabetic retinopathy, CFP - color fundus photographs, CNN - convolutional neural network, AUC - area under the curve

AGE-RELATED MACULAR DEGENERATION

Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in the elderly, and approximately 9% of individuals ages 45-85 are affected worldwide. It's expected to reach 288 million by 2040 [28]. As up to 84% of cases in the early stages do not get diagnosed, screening in individuals older than 65 years at regular intervals is recommended; however, AI-based big solutions are required to conduct widespread centralized screening and reduce the burden on the clinician. In 2013, Grinsven et al. proposed a ML method for detecting and quantifying drusen in fundus images, obtaining an ROC of 0.948, at a level comparable to ophthalmologists. Burlina et al. Our models have trained deep CNNs for AMD severity classification with accuracy of 79.4%, 81.5% and 93.4% respectively. Chou et al. reported an accuracy of 83.67% and sensitivity of 80.76% for the diagnosis of AMD from their deep learning model on an external validation set. Two models have also predicted AMD progression by AI, for example, Waldstein et al. Volume of drusen and hyperreflective foci detected in optical coherence tomography scans by algorithm. Yan et al. used a CNN to predict progression with a AUC of 0.85 [19].

Table 2. Summary of selected studies using artificial intelligence in the diagnosis, stages, and prognosis of age-related macular degeneration [30-34].

Study	Disease	AI Tool	Study Cohort/Database	Imaging Analyzed	Performance Metrics
Burlina et al.	AMD Diagnosis	CNN	67401 images	CFP	AUC = 0,970
					Sensitivity = 83,1%
					Specifity = 93,6 %
					Accuracy = 90,2 %
Bhuiyan et al.	AMD Proggesion	DL	> 4600 participants from AREDS	CFP	Sensitivity = 91% (year 1), 92% (year 2)
					Specifity = 85% (year 1), 84% (year 2)
					Accuracy = 86% (year 1), 85% (year 2)
Banerjee et al.	AMD Proggresion	DL	13954 images	OCT	AUC = 0,96
Schmidt-Erfurth et al.	AMD Proggresion	DL	495 images	OCT	AUC = 0,68
Lee et al.	AMD Diagnosis	DNN	48312 cases, 52690 controls	OCT	AUC = 0,98
					Sensitivity = 84,6%
					Specifity = 91,5%
					Accuracy = 87,6%

CFP - color fundus photographs, AMD - age-related macular degeneration, CNN - convolutional neural network, DL - deep learning, DNN - deep neural network, OCT - optic coherence tomography, AUC - area under the curve.

BIOLOGICAL THERAPIES

For the treatment of several ocular pathologies including age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, and obstruction or occlusion of retinal vessels, Antagonists of Vascular Endothelial Growth Factor (Anti-VEGF) are predominantly administered by means of intravitreal injection [11]. Diabetic macular edema (DME) develops when vascular endothelial growth factor (VEGF), triggering the breakdown of the blood-retinal barrier and leading to macular edema and neovascularization. This clarity has placed anti-VEGF treatment at the center of DME approaches, closing the input offered by old focal photocoagulation.

There are several anti-VEGF agents currently available, including ranibizumab (Lucentis), aflibercept (Eylea), conbercept (Lumin), brolucizumab (Beovu), and off-label use of bevacizumab (Avastin). These drugs vary in molecular structures, binding affinities, and VEGF isoforms targeted. Despite their effectiveness, a large proportion of patients (31.6–65.6%) have persistent edema even after several injections. Such cases typically require frequent treatments, which increases costs and highlights limitations in targeting all factors that drive DME. In addition, some patients show an incomplete response or no response to anti-VEGF therapy, in this case leading to the need for alternative therapeutic measures.

Treatments including, but not limited to, are being developed to combat these obstacles. Biosimilars allow for lower costs, while next-generation drugs, such as smaller molecules and fusion proteins, can target more VEGF isoforms for greater effect. The Port Delivery System (PDS) with ranibizumab is an extended-release system designed to minimize the frequency of injections and maximize patient compliance. Moreover, gene therapy strategies to achieve long-lasting inhibition of VEGF are under investigation for long-acting options. These refinements of DME management and outcomes in a more diverse patient population suggest continued innovations beyond a DME clinical study and report [12].

GENE AND CELLULAR THERAPIES

Exosomes are small extracellular vesicles that can transfer cargo between cells, allowing for intercellular communication; their unique properties make them promising delivery vehicles, especially for retinal diseases. These nanocarriers can cross the blood-retinal barrier (BRB), enhancing treatment outcomes in conditions such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Exosomes minimize systemic side effect profiles associated with conventional treatments by directly administering anti-inflammatory or anti-angiogenic agents to the retina. Yet scaling up production, ensuring purity, and improving targeting to tissues remain challenges. The breakthroughs are improving exosome engineering that address these barriers [13].

Luxturna™ represents the state of the art in gene therapies for inherited retinal diseases (IRDs), specifically Leber Congenital Amaurosis (LCA2), where devices like Luxturna™ are focused on providing a competitive advantage in visual function. This success has prompted the development of gene therapies for other retinal diseases, including AMD. But hurdles like optimal dosing and immune responses persist. Delivery approaches such as subretinal injection (SRI) are associated with risks like retinal detachment and hemorrhage, and other methods (suprachoroidal and intravitreal injections) are still under investigation. Even with these challenges, gene therapies show great potential for treating retinal diseases, and continued research is being conducted to facilitate delivery [14].

NANOMEDICINE TECHNOLOGIES AND RETINAL IMPLANTS:

Due to recent developments in nanotechnology, ocular nanomedicine has progressed dramatically, facilitating the comprehensive delivery of pharmaceuticals, diagnostics, and therapeutics to the eye. The unique properties of nanomaterials such as metal nanoparticles, liposomes, and quantum dots have aided researchers in solving previous challenges in ophthalmology. These materials, having improved bioavailability, increase the chances for drugs to cross the complex barriers of the eye and provide controlled and extended release means to minimize side effects.

Multi-functionalized nanomaterials have also made their way to precision imaging and biosensing. These blockbusters enable very high fidelity diagnostics by surmounting inherent challenges, like ocular autofluorescence, that are otherwise plaguing traditional imaging approaches. Therefore, nanotechnology has become an essential technology for improving the efficiency of ophthalmic medicine and guidance for personalized, minimally invasive treatment [15].

Degenerative retinopathies, including retinitis pigmentosa and age-related macular degeneration, induce blindness by damaging photoreceptor cells. Although some neuronal remodeling takes place, how it affects vision processing is unclear. In response to this range of issues, researchers are developing vision-restoring retinal implants. Current retinal implants only allow rudimentary greyscale light perception; however, patients with these implants can implement simple visual tasks and navigate independently. Previous reviews of retinal implants have tended to be written by the developers of individual devices, with a focus on their designs and limited neutral evaluation. The majority of devices are in the developmental stage, meaning that they require substantial investments, with few published data available. This necessitates an objective review based on the established success criteria. In this review, we will discuss the present status of retinal prostheses with an emphasis on clinical availability, vision restoration, and long-term biocompatibility in patients suffering from degenerative retinopathies [16].

DISCUSSION AND IMPLICATIONS FOR PRACTICE

Improvements in diagnostic, therapeutic, and technology-based innovations in establishing the best treatment pathways for patients with retinal disease have outpaced the evolution of current methods used in ocular trials. However, innovative technologies, including Optical Coherence Tomography (OCT) and its derivative Optical Coherence Tomography Angiography (OCTA), have changed how retinal health is detected and monitored in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) and have become essential tools in the ophthalmologist's armamentarium. They have transformed non-invasive diagnostics, providing insights through excellent cross-sectional and vascular imaging, improving clinical decision-making, and facilitating targeted interventions. But as these technologies become more mainstream, equitable access and cost are real-time concerns.

Ophthalmology is being transformed by the incorporation of artificial intelligence (AI) both in diagnostics and predictive analytics. Through deep learning-based surveillance techniques, AI algorithms enhance diagnostic precision, aid in image interpretation, and provide predictive insights into systemic diseases inferred from ocular images. However, data standardization, algorithm transparency, and the clinical validation of AI systems are also challenges that need to be addressed to gain wider acceptance and incorporation into clinical practice.

Therapies targeting the same root cause have advanced, with anti-VEGF medications transforming the treatment model in retinal vascular diseases and proving effective in preventing vision loss in AMD and diabetic macular edema (DME). Nonetheless, the requirement for repeated injections and unpredictable individual responses indicate the involvement of other ameliorative approaches. Next-generation anti-VEGF modalities, long-acting delivery systems, and gene-based approaches are exciting new developments that seek to overcome these limitations by enabling longer therapeutic action while reducing treatment burden.

Gene and cellular therapies also hold revolutionary potential for previously untreatable retinal conditions. The success of Luxturna™ in treating inherited retinal diseases (IRDs) has inspired research into gene therapies for AMD and other conditions affecting the retina. However, considerable hurdles need to be surmounted in terms of immune responses, best delivery modalities, and scalability for wider clinical relevance.

Challenges for innovation with nanomedicine and retinal prosthetics exist. Nanotechnology contributes to precision in drug delivery, imaging, various applications targeting ocular autofluorescence, and promoting targeted, minimally invasive treatment options. Likewise, retinal prostheses — also in experimental form — hold promise for restoring basic vision in patients suffering from degenerative retinopathies. It will be crucial to continue improving their biocompatibility and functionality, as well as their accessibility before any clinical integration.

CONCLUSIONS

Industry-academic collaboration in the development of innovative ophthalmic technologies is essential. Retinal diseases are a prime area for technological innovation and translation. New standards of diagnostic excellence have emerged with advanced imaging, like OCT, enhancing the ability to identify and accurately monitor retinal pathologies. Concurrently, the application of AI to ophthalmology has improved the indices of diagnosis and provided avenues for systematic monitoring of health through the evaluation of ocular imaging.

Therapeutically, anti-VEGF therapies continue to be the foundation of the management of retinal vascular disease. However, continued advances in next-generation biologics, extended-release systems, and gene therapies underscore the field's ongoing efforts to overcome current limitations and improve patient outcomes. Nanotechnology and exosome-based drug delivery systems also represent breakthrough strategies for treating these patients more effectively.

Retinal prostheses illustrate the opportunity to restore vision in previously untreatable conditions. Although these devices are still under development, their advancement demonstrates how critical multidisciplinary research is to address technical and clinical obstacles.

Moving forward, it will be important for future research to consider how to improve the cost, accessibility, and sustainability of these technologies. Cross-industry collaboration and investment in clinical trials are essential to help usher these innovations from experiment to the frontlines of clinical practice. With multiple advances still on the horizon in managing retinal disease, healthcare professionals now not only have the chance to restore vision, but to significantly impact the quality of life for millions of patients across the globe.

RECOMMENDATIONS

However, the rapid development of modern technologies for the diagnosis and treatment of retinal diseases highlights the need for long-term studies to evaluate the safety and effectiveness. Gene therapies, nanomaterials, and exosome-based drug delivery systems are potential candidates for novel therapies, yet more multicenter clinical trials are needed to bring these techniques into routine clinical use. It will be important to continue monitoring long-term effects and potential side effects of these therapies to optimize treatment protocols and make sure that they are safe for patients.

Moreover, the development of new imaging technologies (i.e., Optical Coherence Tomography (OCT) and the modified one (OCTA)) should emphasize higher imaging precision and also less equipment costs during this time. These efforts could help make diagnostics accessible even in areas with limited medical facilities. Streamlined versions of these systems would be easily integrated into first-contact level health care to expedite the screening for early retinal pathologies.

One more important path includes infusing artificial intelligence (AI) into diagnostic workflows. AI-based solutions assist ophthalmologist not just with assessing retinal images but also predicting therapeutic responses and monitoring disease activity. They require iterative examination of algorithms, their transparency, and integration with pre-existing medical systems to take full advantage of potential. In addition, research regarding the ethics and legal implications of AI, and data protection concerns in relation to AI, continues to be a priority.

Non-invasive modern diagnostic approaches should be established as standards of care in retinal diseases. Techniques like OCTA paired with AI-assisted tools allows for earlier pathology detection and timely therapeutic intervention. These will also improve the treatment outcomes and minimize the number of therapeutic treatment opportunities that patients will need based on their own proclivities.

elemedicine-based solutions and remote health monitoring systems are other advanced technologies that could be made more accessible to improve the quality of care for patients with retinal diseases.. Not only will these systems assist in health monitoring, but also provide access to specialists in remote areas.

That means that the development and implementation of these modern diagnostic and therapeutic technologies for retinal diseases will require continuous improvement of possible tools, and an environment to allow for their mass introduction into clinical practice. Collaboration across various disciplines, the evolution of artificial intelligence algorithms, and improved access to novel technologies will all drive success in the future to address these conditions.

REFERENCES

1. Chew, E. Y., & Swaroop, A. (Eds.). (2021). *Age-related Macular Degeneration. Advances in Experimental Medicine and Biology.* doi:10.1007/978-3-030-66014-7

2. Fung TH, Patel B, Wilmot EG, Amoaku WM. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022 Mar;22(2):112-116. DOI: 10.7861/clinmed.2021-0792. PMID: 35304370; PMCID: PMC8966825.
3. Schick, T., Heimann, H., & Schaub, F. (2020). Netzhautablösung – Teil 1. Klinische Monatsblätter Für Augenheilkunde. DOI: 10.1055/a-1243-1363
4. Kwok JM, Yu CW, Christakis PG. Retinal detachment. CMAJ. 2020 Mar 23;192(12):E312. DOI: 10.1503/cmaj.191337. PMID: 32392514; PMCID: PMC7101175.
5. Javed A, Khanna A, Palmer E, Wilde C, Zaman A, Orr G, Kumudhan D, Lakshmanan A, Panos GD. Optical coherence tomography angiography: a review of the current literature. J Int Med Res. 2023 Jul;51(7):3000605231187933. DOI: 10.1177/03000605231187933. PMID: 37498178; PMCID: PMC10387790.
6. Prahs P, Brandl C, Helbig H, Volz C. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor. Rom J Ophthalmol. 2023 Jul-Sep;67(3):260-266. DOI: 10.22336/rjo.2023.43. PMID: 37876508; PMCID: PMC10591426.
7. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-Related Macular Degeneration: A Review. JAMA. 2024 Jan 9;331(2):147-157. DOI: 10.1001/jama.2023.26074. PMID: 38193957.
8. Zhang L, Van Dijk EHC, Borrelli E, Fragiotta S, Breazzano MP. OCT and OCT Angiography Update: Clinical Application to Age-Related Macular Degeneration, Central Serous Chorioretinopathy, Macular Telangiectasia, and Diabetic Retinopathy. Diagnostics (Basel). 2023 Jan 8;13(2):232. DOI: 10.3390/diagnostics13020232. PMID: 36673042; PMCID: PMC9858550.
9. Gheorghe CM. AI-based technology in Ophthalmology: the key to the future. Rom J Ophthalmol. 2023 Oct-Dec;67(4):325. DOI: 10.22336/rjo.2023.52. PMID: 38239422; PMCID: PMC10793375.
10. Zhou, Y., Chia, M.A., Wagner, S.K. *et al.* A foundation model for generalizable disease detection from retinal images. *Nature* 622, 156–163 (2023). DOI: 10.1038/s41586-023-06555-x
11. Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020 Mar;15(2):199-210. DOI: 10.1007/s11739-019-02253-7.Epub 2019 Dec 17. PMID: 31848994.
12. Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, Qiu Q. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362. DOI: 10.3390/cells11213362. PMID: 36359761; PMCID: PMC9655436.
13. Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. Advances in exosome therapies in ophthalmology-From bench to clinical trial. Acta Ophthalmol. 2022 May;100(3):243-252. DOI: 10.1111/aos.14932. Epub 2021 Jun 11. PMID: 34114746.
14. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021 Feb 3;29(2):464-488. DOI: 10.1016/j.ymthe.2020.12.007. Epub 2020 Dec 10. PMID: 33309881; PMCID: PMC7854298.
15. Tang Z, Fan X, Chen Y, Gu P. Ocular Nanomedicine. Adv Sci (Weinh). 2022 May;9(15):e2003699. DOI: 10.1002/advs.202003699. Epub 2022 Feb 12. PMID: 35150092; PMCID: PMC9130902.
16. Chuang, A. T., Margo, C. E., & Greenberg, P. B. (2014). *Retinal implants: a systematic review: Table 1. British Journal of Ophthalmology, 98(7), 852–856.* DOI: 10.1136/bjophthalmol-2013-303708
17. De Fauw, J., Ledsam, J. R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell, S., … Ronneberger, O. (2018). *Clinically applicable deep learning for diagnosis and referral in retinal disease. Nature Medicine.* DOI: 10.1038/s41591-018-0107-6
18. Srinivasan, P. P. et al. Fully automated detection of diabetic macular edema and dry age-related macular degeneration from optical coherence tomography images. Biomed. Opt. Express 5, 3568–3577 (2014).
19. Parmar, U. P. S., Surico, P. L., Singh, R. B., Romano, F., Salati, C., Spadea, L., Musa, M., Gagliano, C., Mori, T., & Zeppieri, M. (2024). Artificial Intelligence (AI) for Early Diagnosis of Retinal Diseases. *Medicina*, *60*(4), 527. DOI:10.3390/medicina60040527
20. Abràmoff M.D., Lou Y., Erginay A., Clarida W., Amelon R., Folk J.C., Niemeijer M. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset through Integration of Deep Learning. Investig. Opthalmology Vis. Sci. 2016;57:5200. DOI: 10.1167/iovs.16-19964
21. Pires R., Avila S., Wainer J., Valle E., Abramoff M.D., Rocha A. A data-driven approach to referable diabetic retinopathy detection. Artif. Intell. Med. 2019;96:93–106. DOI: 10.1016/j.artmed.2019.03.009
22. Jiang H., Yang K., Gao M., Zhang D., Ma H., Qian W. An Interpretable Ensemble Deep Learning Model for Diabetic Retinopathy Disease Classification; Proceedings of the 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); Berlin, Germany. 23–27

July 2019; pp. 2045–2048.

23. Esfahani M.T., Ghaderi M., Kafiyeh R. Leonardo Electronic Journal of Practices and Technologies Classification of diabetic and normal fundus images using new deep learning method. Leonardo Electron. J. Pract. Technol. 2018;17:233–248.
24. Pratt H., Coenen F., Broadbent D.M., Harding S.P., Zheng Y. Convolutional Neural Networks for Diabetic Retinopathy. Procedia Comput. Sci. 2016;90:200–205. DOI:10.1016/j.procs.2016.07.014
25. Zhang W., Li D., Wei Q., Ding D., Meng L., Wang Y., Zhao X.Y., Chen Y.X. The Validation of Deep Learning-Based Grading Model for Diabetic Retinopathy. Front. Med. 2022;9:839088. DOI: 10.3389/fmed.2022.839088
26. Katz O., Presil D., Cohen L., Nachmani R., Kirshner N., Hoch Y., Lev T., Hadad A., Hewitt R.J., Owens D.R. Evaluation of a New Neural Network Classifier for Diabetic Retinopathy. J. Diabetes Sci. Technol. 2022;16:1401–1409. DOI: 10.1177/19322968211042665
27. Flaxel C.J., Adelman R.A., Bailey S.T., Fawzi A., Lim J.I., Vemulakonda G.A., Ying G. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127:P66–P145. DOI: 10.1016/j.ophtha.2019.09.025
28. Colijn J.M., Meester-Smoor M., Verzijden T., de Breuk A., Silva R., Merle B.M.J., Cougnard-Grégoire A., Hoyng C.B., Fauser S., Coolen A., et al. Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe. Ophthalmology. 2021;128:1039–1049. DOI: 10.1016/j.ophtha.2020.11.024
29. Hamel C.P., Meunier I., Arndt C., Salah SBen Lopez S., Bazalgette C., Zanlonghi X., Arnaud B., Defoort-Dellhemmes S., Puech B. Extensive macular atrophy with pseudodrusen-like appearance: A new clinical entity. Am. J. Ophthalmol. 2009;147:609–620. DOI: 10.1016/j.ajo.2008.10.022
30. Burlina, P.; Pacheco, K.D.; Joshi, N.; Freund, D.E.; Bressler, N.M. Comparing humans and deep learning performance for grading AMD: A study in using universal deep features and transfer learning for automated AMD analysis. Comput. Biol. Med. 2017, 82, 80–86. DOI: 10.1016/j.compbiomed.2017.01.018
31. Bhuiyan, A.; Wong, T.Y.; Ting, D.S.W.; Govindaiah, A.; Souied, E.H.; Smith, R.T. Artificial Intelligence to Stratify Severity of Age-Related Macular Degeneration (AMD) and Predict Risk of Progression to Late AMD. Transl. Vis. Sci. Technol. 2020, 9, 25. DOI: 10.1167/tvst.9.2.25
32. Banerjee, I.; de Sisternes, L.; Hallak, J.A.; Leng, T.; Osborne, A.; Rosenfeld, P.J.; Gregori, G.; Durbin, M.; Rubin, D. Prediction of age-related macular degeneration disease using a sequential deep learning approach on longitudinal SD-OCT imaging biomarkers. Sci. Rep. 2020, 10, 15434. DOI: 10.1038/s41598-020-72359-y
33. Schmidt-Erfurth, U.; Waldstein, S.M.; Klimscha, S.; Sadeghipour, A.; Hu, X.; Gerendas, B.S.; Osborne, A.; Bogunovic, H. Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. Investig. Opthalmology Vis. Sci. 2018, 59, 3199. DOI: 10.1167/iovs.18-24106
34. Lee, C.S.; Baughman, D.M.; Lee, A.Y. Deep Learning Is Effective for Classifying Normal versus Age-Related Macular Degeneration OCT Images. Ophthalmol. Retina 2017, 1, 322–327. DOI: 10.1016/j.oret.2016.12.009

back